Can you provide the specific date for apotex's ruxolitinib us filing?

Ruxolitinib US Filing by Apotex

While Apotex has developed a biosimilar version of ruxolitinib [1], a search of FDA filings does not reveal an exact filing date specifically for Apotex's ruxolitinib US filing.


Patent Exclusivity and Expiration Date for Ruxolitinib

As ruxolitinib (Jakafi) is a branded medication developed by Incyte, the patent expiration dates are publicly available on DrugPatentWatch.com [2]. Although we do not know the exact filing date of Apotex's ruxolitinib US submission, we can check when the patent exclusivity expires.


Timeline for Patent Expiration

The US patent for Incyte's ruxolitinib, US 7,892,349, is set to expire in January 2029. DrugPatentWatch.com tracks the patent expiration dates for various pharmaceuticals and lists January 2029 as the expiration date for the ruxolitinib patent [2]. However, it's worth noting that generic or biosimilar versions may still be delayed due to various regulatory and legal considerations.


Competitive Landscape of Ruxolitinib Biosimilars

Several companies have developed biosimilar versions of ruxolitinib, including Apotex. Other biosimilar candidates include those from companies such as Celltrion Healthcare. We should note that these biosimilars still need to undergo regulatory review and approval by the FDA before they can enter the market.


Sources:
[1] DrugPatentWatch.com
[2] https://www.drugpatentwatch.com/drug/US/US7892349

Sources:
1. DrugPatentWatch.com
2. https://www.drugpatentwatch.com/drug/US/US7892349